PGAB.F Stock Overview

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. More details

PGAB.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 31.7% per year over past 5 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK2M)

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Prostatype Genomics AB (publ) Competitors

Trevena

OTCPK:TRVN

US$1.1m

Regen BioPharma

OTCPK:RGBP

US$1.3m

AXIM Biotechnologies

OTCPK:AXIM

US$2.1m

International Stem Cell

OTCPK:ISCO

US$880.5k

Price History & Performance

Summary of share price highs, lows and changes for Prostatype Genomics
Historical stock prices
Current Share Price	SEK 0.36
52 Week High	SEK 0.40
52 Week Low	SEK 0.36
Beta	0.34
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.40%

Recent updates

Shareholder Returns

	PGAB.F	US Biotechs	US Market
7D	0%	-7.7%	1.2%
1Y	n/a	-13.5%	7.7%

Return vs Industry: Insufficient data to determine how PGAB.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PGAB.F performed against the US Market.

Price Volatility

Is PGAB.F's price volatile compared to industry and market?
PGAB.F volatility
PGAB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.8%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	4.1%

Stable Share Price: PGAB.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PGAB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	6	Fredrik Rickman	www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company’s test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision.

Prostatype Genomics AB (publ) Fundamentals Summary

How do Prostatype Genomics's earnings and revenue compare to its market cap?
PGAB.F fundamental statistics
Market cap	US$1.15m
Earnings (TTM)	-US$4.26m
Revenue (TTM)	US$199.17k

5.8x

P/S Ratio

-0.3x

P/E Ratio

Is PGAB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PGAB.F income statement (TTM)
Revenue	SEK 1.92m
Cost of Revenue	SEK 22.36m
Gross Profit	-SEK 20.44m
Other Expenses	SEK 20.61m
Earnings	-SEK 41.05m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 23, 2025

Earnings per share (EPS)	-6.12
Gross Margin	-1,065.54%
Net Profit Margin	-2,140.30%
Debt/Equity Ratio	0.2%

How did PGAB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/08 10:06
End of Day Share Price	2025/03/31 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prostatype Genomics AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Johan Unnerus	Redeye

Prostatype Genomics OTCPK:PGAB.F Stock Report